Peter Langmuir

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

Samuel A. Wells, Bruce G. Robinson, Robert F. Gagel et al. · Journal of Clinical Oncology · 2011 · 1.6K citations · Full text

Medicine, Oncology, Pharmacology +6

Quantifying the Frequency of Alloreactive T Cells In Vivo: New Answers to an Old Question

Elliot J. Suchin, Peter Langmuir, Ed Palmer et al. · The Journal of Immunology · 2001 · 519 citations · Full text

Life Sciences, Cell Biology, Immunology +15

Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease

Robert Zeiser, Nicola Polverelli, Ron Ram et al. · New England Journal of Medicine · 2021 · 499 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

Roy S. Herbst, Yan Sun, Wilfried Eberhardt et al. · The Lancet Oncology · 2010 · 419 citations · Full text

Medicine, Oncology, Pharmacology +9

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses

Srđan Verstovšek, Jason Gotlib, Ruben A. Mesa et al. · Journal of Hematology & Oncology · 2017 · 298 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13